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Mycobacterium ulcerans gives rise to severe skin
ulceration that can be associated with considerable illness.
The cost of diagnosis, treatment, and lost income has
never been assessed in Australia. A survey of 26 confirmed
cases of the disease in Victoria was undertaken. Data were
collected on demographic details, diagnostic tests, treat-
ment, time off work, and travel to obtain treatment. All costs
are reported in Australian dollars in 1997–98 prices. The
cost varies considerably with disease severity. For mild
cases, the average direct cost is $6,803, and for severe
cases $27,681. Hospitalization accounts for 61% to 90% of
costs, and indirect costs amount to 24% of the total per
case. M. ulcerans can be an expensive disease to diag-
nose and treat. Costs can be reduced by early diagnosis
and definitive treatment. Research is needed to find cost-
effective therapies for this disease. 
M
ycobacterium ulcerans causes disfiguring ulcers
with substantial illness (1). These distinctive ulcers
were first described in Australia in 1948 and given the
name Bairnsdale ulcer because of their focal distribution.
In Australia, in addition to the Bairnsdale area in
Gippsland, Victoria, cases have been reported from foci in
Queensland and the Northern Territory (1,2).
Until 1982 to 1983, when three cases were detected
near Western Port Bay, cases in Victoria were confined to
the Bairnsdale area. Since 1983, over 50 cases have been
recorded in Victoria outside this area, and the disease
appears to be spreading progressively westward. An out-
break on Phillip Island in 1993 and 1994 resulted in 27
reported cases (3,4). From 1990 to 1997, 22 cases within
approximately 70 km of Melbourne were reported, 19 of
these on the Mornington Peninsula with 12 in the
Frankston/Langwarrin area (Figure). For the first time,
cases were detected west of Melbourne in 1998, and the
number occurring in that area is increasing (Victorian
Mycobacterium Reference Laboratory and Department of
Human Services).
Treatment involves hospitalization for debridement and
often skin grafting, which frequently has to be repeated
(5–7). Patients are frequently absent from work for long
periods, which results in considerable cost to the commu-
nity. In Australia, the cost of the diagnosis, treatment, and
lost income has never been accurately assessed. The objec-
tive of this study was to assess the direct and indirect cost
of  M. ulcerans infection occurring outside previously
known disease-endemic areas of Victoria, Australia.
Methods
A survey of 26 cases of the disease in Victoria was
undertaken. A case-patient was defined as a person with a
clinical lesion with histologic, culture, or polymerase chain
reaction evidence of M. ulcerans infection. Eligible patients
with M. ulcerans were contacted and sent a questionnaire
requesting demographic data, treatment information, time
off work, and distance traveled to obtain treatment. One or
more phone calls were made by the primary investigator to
clarify and expand the data and seek evidence. Calls often
lasted for 1 hour. Pathology reports, patient diaries, and
information from physician files were used, where possible,
to confirm information. The eligibility criteria were based
on age (6 months of age to 100 years) and date of onset of
the disease (January 1, 1991–August 31, 1998). Cases
occurring in the disease-endemic areas of Gippsland and
Phillip Island were excluded.
Two sources were used to find cases. The first source
was the Victorian Mycobacterium Reference Laboratory. It
receives specimens either directly, when mycobacteria cul-
tures are requested, or as cultures from other laboratories
to confirm mycobacterium and determine the species. The
second source included records kept by a well-known
Victoria pathologist with a longstanding interest in the dis-
ease; other pathologists frequently refer specimens from
patients with suspected cases to this physician. 
Treating physicians were contacted and approval
sought from them before attempts were made to contact
their patients. All known case-patients were contacted, and
the questionnaire was completed by telephone interview.
When a telephone number was incorrect, all leads were
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Territory, Australiafollowed as far as possible to locate the patient. Private and
public hospitals might have served as a third source for
case finding, but they are not obligated to report cases of
M. ulcerans, and their record-keeping systems are such
that abstracting cases would be very difficult.
In total, 32 persons with M. ulcerans who met the case
definition during the study period were located. Of these,
26 (81%) could be contacted. All agreed to complete the
questionnaire (100% response rate).
Patients were divided into three categories on the basis
of their clinical history. Patients with a mild disease had a
biopsy and excision only. Patients with moderate disease
had one lesion only, which was treated with biopsy and
excision, with only one skin graft required. Patients with
severe disease had multiple lesions, multiple debride-
ments, or multiple skin grafts. 
Medical, hospital, and other services used to diagnose
and treat each patient, the time lost from his or her usual
occupation, along with the cost of transportation to care
facilities for patients traveling over 50 km each way were
recorded. Physicians who treated the patients, hospital
records, old prescriptions, and the like were used to verify
cases.
Cost Data
All cost data are expressed in Australian dollars using
Australian financial year 1997–1998 prices. The unit cost
of a visit to a local physician (general practitioner) and to
a specialist (apart from inpatient care) was estimated by
using the average fee charged across a range of relevant
Medicare Benefits Schedule (MBS) item numbers for the
year 1997–98 (Table 1). For specialists, the average was
calculated across both first and subsequent visits. Patients
treated as outpatients had a biopsy of the lesion with
microscopy and culture for mycobacteria. MBS fees for
the biopsy (MBS item no. 30071) and for the microscopy
and culture (MBS item no. 69207) were taken as the unit
costs of these tests.
The cost of blood tests required for monitoring a patient
who was receiving special medications was estimated by
using the MBS fee for liver function tests (MBS item no.
66211). Most patients receiving special medications would
have these tests at least monthly.
Hospital costs were calculated according to whether the
patient was treated in a public or a private hospital. For
both hospital types, the per diem cost for the first 4 days of
hospitalization was based on the national average cost per
day for DRG 505 (other skin graft ± debridement) in
1996–97. The per diem cost for any days of hospitalization
in excess of 4 was then taken as the overall average cost
per day. This per diem cost is the same for both public and
private hospitals (8).
The cost of antimicrobial agents was estimated by using
the cost paid by the patient (if known) or the costs paid by
a hospital pharmacy to purchase the drug. These costs were
for bulk purchases of the various medications. When the
name of the antimicrobial agent was unknown, the cost of
a course of antimicrobial agents was estimated at $5 per
course. Medications specific for mycobacteria included
clarithromycin 500 mg twice daily, rifampicin 600 mg
daily, and ethambutol 400 mg three times/day. Hospitals’
costs for these drugs were used to estimate the cost of each
patient’s course of treatment.
A visiting nurse attended the homes of some patients.
The Royal District Nursing Service estimates that the aver-
age cost of a home visit was $44.10/hour (The Service, pers.
comm.). When this figure is used, an average visit (includ-
ing travel time) for dressing changes was estimated at 40
minutes. Thus, a rate of $29/visit was used as the estimated
cost of a visit. Anumber of patients had heat treatment with
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Figure. Cases of Mycobacterium
ulcerans occurring in areas of
Victoria (southeastern Australia),
where disease is nonendemic,
January 1990–August 1998. various devices at variable costs. If known, the actual cost
was included. Some patients used electrical devices such as
electric blankets continuously and for prolonged periods. If
costs were not known, a standard rate was used.
Dressings and bandages used by patients were priced at
a commercial pharmacy, and the likely cost to the patients
was calculated on the basis of their reported use. When
details of the amount used were not obtainable, a standard
rate for bandages and dressings was used. The cost of treat-
ment not routinely incurred was estimated, where possible,
for individual patients. These items included aids such as
crutches, extra investigations such as ultrasound, occupa-
tional therapy, and physiotherapy.
The value of time lost from work because of illness was
calculated by using an estimate of average weekly earnings
(9). No cost was included for travel time per se or the time
lost by children from school or kindergarten. The time lost
from work by parents as a result of a child’s illness or hos-
pitalization was also not included. No cost was included
for the time lost from normal duties by retired persons or
those engaged in home duties at the time of their illness.
An estimate for travel expenses was included only for
patients whose treatment required substantial travel (>50
km each way). 
Results
Direct Costs
The average direct cost of treating patients with this
disease was $14,608 (Table 2). This cost differed most
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Table 2. Average direct cost for diagnosing and treating a patient with Mycobacterium ulcerans 
  Cost in Australian dollars, 1997–1998 prices (% of column total)
a 
  Mild case  Moderate case  Severe case  All cases 
No. of cases  12  8  6  26 
Medical practitioner costs       
General practitioner visits  274  253  82  223 
Specialist visits  377  739  628  546 
Total visits  651 (10)  992 (6)  710 (3)  769 (5) 
Other costs 
Hospitalization  4,139 (61)  12,607 (76)  24,840 (90)  11,522 (79) 
Dressings  1,134 (17)  1,206 (7)  1,230 (4)  1,178 (8) 
Medications  357 (5)  959 (6)  449 (2)  561 (4) 
Home nursing  458 (7)  680 (4)  211 (1)  468 (3) 
Laboratory costs  49 (0.7)  57 (0.3)  31 (0.1)  47 (0.3) 
Heat treatment  15 (0.2)  24 (0.1)  210 (0.8)  63 (0.4) 
Total direct costs  6,803 (100)  16,525 (100)  27,681 (100)  14,608 (100) 
aAny differences between totals and sums of components are due to rounding.   
Table 1. Cost of diagnosing and treating Mycobacterium ulcerans cases (Australian dollars, 1997–98 prices)
a 
Item   Unit  Cost 
General practitioner visits  Visit  $24.68 
Specialist visits  Visit  $57.98 
Hospitalization  Cost per day for DRG 505 (other skin graft ± debridement): public hospital  $776 
  Cost per day for DRG 505 (other skin graft ± debridement): private hospital  $935 
  Hospitalization over 4 days  $598/day 
Dressings  Bandages
 b  $18/week 
  Dressings
 b  $20/week 
Medications  Agent unknown
  $5/course 
  Clarithromycin 500 mg twice daily  $3.89/dose 
  Rifampicin 600mg daily  $0.36/dose 
  Ethambutol 400 mg three times/day  $0.71/dose 
Home nursing  Visits  $29/visit 
Laboratory costs  Biopsy (MBS item no. 30071)  $38.80 
  Microscopy and culture (MBS item no. 69207)  $28.00 
  Liver function tests (MBS item no. 66211)  $16.80 
Heat treatment  Day
b  $3.00/day 
Lost income  Day
b  Average weekly earnings of 
$766.80 
Transport  Kilometer
b  $0.50/km 
aDRG, diagnosis-related group; MBS, Medicare Benefits Schedule. 
bIf known, the actual cost was used; otherwise, it was estimated from the unit cost.  noticeably between patients who required, or did not
require, skin grafting. The average cost increased from
$6,803 for patients not requiring a skin graft to $27,681 for
those requiring multiple procedures. 
Hospitalization was by far the most expensive compo-
nent of the direct costs. This cost ranged from an average
of $4,139 (61% of total direct cost) for mild cases to an
average of $24,840 (90%) for severe cases. The second
greatest expense in all categories of the disease was for
dressings, approximately $1,200 for all categories of dis-
ease severity. This cost was much less than the cost of hos-
pitalization in all categories but it was equivalent to
approximately 5% of the cost of hospitalization in the
severe disease category. In this category, the cost of dress-
ings was more than double that of medications. 
The third greatest expense in all categories was medical
care. As the disease severity increased, the cost of medical
care shifted from general practitioners to specialist care.
The average cost of specialist visits ranged from $377 for
mild cases to $739 for patients who received one skin graft,
while average general practitioner costs fell from $274 for
mild cases to $82 for severe cases. For patients with mild
cases, the cost of outpatient specialist visits accounted for
58% of the cost of medical practitioner care. For patients
with severe disease, this cost increased to 88%. 
For the moderate and severe categories, medications
were the next greatest expense, which included regular
antimicrobial agents and drugs targeted for mycobacteria.
These latter medications accounted for most of the cost of
medications. Although approximately 50% of patients in
each category were treated with these expensive drugs,
those in the moderate category incurred the greatest
expense as they had the longest courses of these medica-
tions. The cost per case in the moderate category was twice
that in the severe category.
Only nine patients received home nursing care. One of
these received 108 visits and another 96 visits. More cases
in the moderate disease category received home nursing
care than those in the other categories (five of the eight
cases compared to two of the six in the severe category).
Home nursing service in the moderate category cost an
average of $680.
Heat treatment and laboratory costs were the least
expensive components of the treatment costs. Heat treat-
ment was mainly confined to the severe disease category.
Laboratory costs were similar across all categories.
Indirect Costs and Transport Costs
Time missed from regular occupation and income loss-
es were estimated for nine patients who had regular jobs at
the onset of the disease (six mild, one moderate and two
severe cases) (Table 3). Of the 17 for whom income losses
were not estimated, 9 were children and 5 were retired per-
sons. Three were housewives who had difficulty estimating
the amount of lost performance. A monetary value is diffi-
cult to determine for this occupation, and thus no estimate
was included for their time or financial loss (Table 3). The
average income loss for the nine patients increased as the
severity of the disease increased, from $12,451 for those
with mild cases to $16,431 and $19,170 for those with
moderate and severe cases, respectively. Income losses for
these nine patients were 0–$40,000. Average income losses
(including for unemployed patients) are seen in Table 4.
A small number of case-patients (n = 3) incurred major
costs as a result of transportation from the country to city
centers for treatment. The greatest cost estimate for this
transport was $2,900 for one patient with severe disease. A
patient with a mild case incurred transport costs of $1,000
and a patient with a moderate case, $46. Averaged across
all patients within each severity grouping, the average
transport cost per patient was $83, $6, and $483 for the
mild, moderate and severe groups, respectively (Table 4).
Discussion 
M. ulcerans is costly to treat. This study found that the
average cost of diagnosing and treating a case was
$14,608. This figure is approximately seven times the
average health expenditure per person in Australia in
1997–98 of $2,557 (10). Hospitalization costs form most
of the overall costs, accounting for 90% of the total cost for
severe cases and 79% for all cases. Indirect costs account-
ed for 25% of the overall (direct, indirect, and transporta-
tion) cost but considerably more for individual patients.
For those with mild disease, income losses accounted for
47% of the overall cost. 
These cost assessments are conservative for several rea-
sons. First, most patients were treated in public hospitals as
public patients; in Australia, such treatment is usually less
costly than treating a private patient. Thus these costs
could have been substantially higher if more cases were
treated privately in Australia and could vary substantially
in other populations. Second, income losses would have
been much greater if more patients had been in the income-
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Table 3.Time missed from work or school as a result of Mycobacterium ulcerans infection, January 1, 1991–August 31,1998 
  Categorization of case (n  = 23) 
Days missed  Mild (n = 11)  Moderate (n = 8)  Severe (n = 4)  All 
Days missed from work or school (median)
a  2  21  159  28 
Range  0–365  0–150  0–548  0–548 
aSome patients were retired, and some illness occurred during school holidays. generating age group. Third, the cost of impaired produc-
tivity of parents caring for their children and accompany-
ing them for appointments and hospitalizations was not
included in this study, but this cost is likely to have been
considerable.
The patients who had one skin graft incurred the high-
est cost for medications because they were treated with
longer courses of drugs specific for mycobacteria. Three of
these patients were treated for >6 months. These patients
were given a trial of medication in an attempt to avert the
need for surgery or as an adjunct to surgery in an attempt
to prevent recurrence of the disease. 
The marked decrease in general practitioner costs in
severe cases reflects the referral pattern for this disease.
Some patients with severe disease had previous contact
with a specialist (usually a surgeon) as a result of treatment
for a previous lesion, or they required more extensive sur-
gery and skin grafting, which general practitioners would
not normally perform. As patients with severe cases
received more treatment as inpatients, and the cost of sur-
geon visits while in the hospital were included in the hos-
pital charges, the cost of specialist treatment incurred by
the patient does not clearly reflect the amount of care they
received.
Variation around the mean cost within each category of
disease severity was marked. Some of this variation was
due to the lack of standardized, accepted treatment
regimes. In addition, delays until definitive treatment var-
ied greatly between patients, sometimes because of diffi-
culties in making the correct diagnosis. This wide range
probably accounted for the failure of indirect costs to
increase in direct proportion to disease severity.
Alimitation of this study was its reliance upon a patient
questionnaire to collect data on diagnosis, treatment serv-
ices received, and time off work. Because of the consider-
able amount of time that had lapsed since their illness,
some patients had difficulty accurately recalling details of
the events in their disease history. The number of visits to
physicians and the duration of particular events such as
hospitalization or time missed from work were most diffi-
cult to recall precisely. Some patients provided very accu-
rate information because of diaries or prescriptions that
they had kept during their illness or because of records
from hospitals and the physicians who treated them.
Validating some information provided by patients was
difficult. The date of onset, time before seeking medical
help, and date of cure were frequently not documented and
may be difficult to determine accurately. Where possible,
attempts were made to validate dates and number of physi-
cian visits or duration of hospitalization, but insufficient
resources were available to validate all data provided by
patients. A prospective study, performed at the time of an
outbreak of this disease, would be useful to more accurate-
ly determine the cost of treatment.
The early diagnosis and implementation of effective,
definitive treatment would greatly reduce both the illness
and economic impact from M. ulcerans infection. Education
of medical practitioners and the public is required. If com-
munity awareness of this disease is increased, patients will
seek treatment earlier. Educating medical practitioners
about the clinical features of this disease and its recent geo-
graphic spread are essential for early diagnosis and appro-
priate treatment to be promptly implemented. Since this
disease is very appropriate for nursing assistance at home,
hospitalization costs can be drastically reduced by imple-
menting this method of treatment after surgery. Early and
definitive treatment would also substantially reduce the time
missed from work and the associated cost.
The role of medication directed against mycobacteria,
heat therapy, and other therapies reported as helpful by
individual patients requires investigation. An alternative to
the extensive surgery currently required by most patients
would greatly reduce the illness and cost of this disease.
Recently, much progress has been made in detecting these
bacteria in the environment and in rapidly diagnosing
lesions (11,12). 
M. ulcerans is of increasing public health concern
worldwide. In African countries, treatment costs for one
case far exceed the governmental health spending per capi-
ta (13). The increasing numbers of cases in many countries,
the increasing number of countries affected, and the sub-
stantial disability and loss of income that result from this
disease underscore the need for continuing research into
rapid diagnostic methods and cost-effective treatments. 
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Table 4. Average aggregated cost per case of Mycobacterium ulcerans cases, January 1991–August 1998 (26 cases) 
  Cost in Australian dollars, 1997–98 prices (percentage of column total)
a 
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